Indeed, for every target tested (ATG9A, YTHDF3, EHD1, ABHD5, and AP2B1) there is a PD-specific rescue of homeostasis following treatment with LRRK2 inhibitor (Fig. 7). This evidence concerns the gene ATG9A and Parkinson disease.